What 5 Analyst Ratings Have To Say About Dianthus Therapeutics
Ratings for Dianthus Therapeutics (NASDAQ:DNTH) were provided by 5 analysts in the past three months, showcasing a mix…
What 5 Analyst Ratings Have To Say About Dianthus Therapeutics
Across the recent three months, 5 analysts have shared their insights on Dianthus Therapeutics (NASDAQ:DNTH), expressing a variety…
Decoding 4 Analyst Evaluations For Dianthus Therapeutics
Across the recent three months, 4 analysts have shared their insights on Dianthus Therapeutics (NASDAQ:DNTH), expressing a variety…
Why Dianthus Therapeutics (DNTH) Stock Is Exploding Higher
Dianthus Therapeutics shares traded higher by 37% Monday. The company announced a $230 million private placement.
Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst
Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the
Dianthus’ Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand – Analyst
Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics.
Benzinga’s Top Ratings Upgrades, Downgrades For September 28, 2023
Upgrades According to Northcoast Research, the prior rating for Essential Utilities Inc (NYSE:WTRG) was changed from Neutral to…